The U.S. Food and Drug Administration (FDA) has approved the first-ever direct-acting drug designed to treat advanced stages of pancreatic adenocarcinoma. This disease is considered one of the most aggressive and deadly forms of cancer. The decision to authorize the drug was made about six months ahead of schedule to accelerate patient access to this therapy.

Features of Pancreatic Adenocarcinoma

Adenocarcinoma accounts for 90% to 95% of all diagnosed cases of pancreatic cancer. In the United States, approximately 67,000 people receive this diagnosis each year. Although this disease represents only about 3% of all detected cancers, the mortality rate among patients remains extremely high. This is largely because the tumor develops without symptoms for a long time, is usually diagnosed at a late stage, and traditional treatment methods have shown limited effectiveness.

Mechanism of Action of the New Drug

The new medication targets the RAS protein, which for a long time was considered difficult to inhibit with drugs. Normally, this protein regulates cell growth and division, but when mutated, it leads to uncontrolled cell proliferation and the formation of malignant tumors. Mutations in RAS genes are found in the majority of pancreatic cancer patients, making the development of an inhibitor that blocks this protein a significant scientific breakthrough.

The Drug and Clinical Trial Results

The new drug, named “Rasonk,” was developed by the biotechnology company Revolution Medicines and is available in tablet form for daily use. It has been approved for adult patients with metastatic cancer who have already undergone at least one course of systemic chemotherapy or are unable to tolerate it due to health reasons.

In clinical trials involving 500 participants, the drug demonstrated twice the effectiveness compared to existing treatments: the median overall survival for patients taking Rasonk was 13.2 months, whereas with standard chemotherapy, this figure did not exceed 6.7 months. The drug has been granted “breakthrough therapy” and “orphan drug” status (for the treatment of rare and life-threatening diseases).

Side Effects

During studies, the main side effects identified included skin rash, diarrhea, inflammation of the oral mucosa (stomatitis), nausea, abdominal pain, fatigue, swelling, and bleeding.

The introduction of this new drug expands treatment options for patients with a diagnosis that was previously considered almost hopeless.